Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 21

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 21
---
 shareholder as of the Record Date (as defined below), and you are entitled to vote to approve the matters set forth herein. This document serves as: •a proxy statement of Aptorum used to solicit proxies by the Aptorum Board for the Special Meeting to vote on the matters set forth herein; and •a prospectus of Aptorum used to offer shares of Aptorum Delaware common stock to be issued in exchange for shares of DiamiR common stock in the Merger (other than dissenting shares). Q:What is a proxy? A:A proxy is another person that you legally designate to vote your stock. If you designate someone as your proxy in a written document, that document is also called a “proxy” or a “proxy card.” If you are a “street name” holder, you must obtain a proxy from your broker or nominee in order to vote your shares during the Special Meeting. Q:What is a proxy statement? A:A proxy statement is a document that regulations of the SEC require that we give to you when we ask you to sign a proxy card to vote your stock at the Special Meeting. Q:What is the Merger? A:Aptorum and DiamiR entered into the Merger Agreement on July 14, 2025, a copy of which is attached to this proxy statement/prospectus as Annex A. The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, Merger Sub will merge with and into DiamiR, with DiamiR continuing as a wholly owned subsidiary of Aptorum and the surviving corporation of the Merger. This transaction is referred to in this proxy statement/prospectus as the “Merger.” In connection with the Merger, Aptorum will change its corporate name to “Niki BioSolutions, Inc.” Q:What will DiamiR securityholders receive in the Merger? A:At the Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each then -outstandingshare of DiamiR common stock will be converted into a number of shares of Aptorum Delaware common stock equal to the Conversion Ratio (described in more detail in the section titled “The Merger Agreement — Conversion Ratio”). For a more complete description of the treatment of DiamiR securities in the Merger, please see the sections titled “The Merger Agreement — Merger Consideration,” and “The Merger Agreement — Conversion Ratio”. Q:What will Aptorum security